CKD Bio Corp.
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
063160 | KO
Overview
Corporate Details
- ISIN(s):
- KR7063160006
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 서대문구 충정로 8, 서울특별시
- Website:
- https://www.ckdbio.com/en/home
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CKD Bio Corp. is a biopharmaceutical company specializing in the development and manufacturing of probiotics and active pharmaceutical ingredients (APIs). Leveraging over 50 years of expertise in fermentation technology and chemical synthesis, the company's core activities include the production of fermentation-based APIs, such as antibiotics, ß-lactamase inhibitors, and immunosuppressants. It also focuses on the research and development of next-generation probiotics through its dedicated microbiome research division. Additionally, CKD Bio provides Contract Manufacturing Organization (CMO) services for APIs and intermediates, utilizing its cGMP-certified production facilities. The company manages a fully integrated process from microbial strain development and fermentation to purification and final synthesis, aiming for global leadership in biotechnology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-17 00:00 |
Regulatory News Service
투자판단관련주요경영사항
|
Korean | 7.4 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 912.4 KB | ||
| 2025-07-25 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 968.8 KB | ||
| 2025-04-25 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.2 KB | ||
| 2025-04-09 00:00 |
Regulatory News Service
투자판단관련주요경영사항 (티엠버스주200단위(클로스트리디움보툴리눔독소A형)제조판매 품목허가 신청)
|
Korean | 14.0 KB | ||
| 2025-04-01 00:00 |
Regulatory News Service
투자판단관련주요경영사항 (티엠버스주100단위(클로스트리디움보툴리눔독소A형) 제조판매 품목허가 승인)
|
Korean | 7.5 KB | ||
| 2025-03-26 00:00 |
Post-Annual General Meeting Information
정기주주총회결과
|
Korean | 18.6 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.3 KB | ||
| 2025-03-18 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.3 MB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 7.1 KB | ||
| 2025-02-25 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.8 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 111.3 KB | ||
| 2025-02-25 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 89.4 KB | ||
| 2025-01-24 00:00 |
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 11.8 KB |
Automate Your Workflow. Get a real-time feed of all CKD Bio Corp. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CKD Bio Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CKD Bio Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
